# US 10,945,971 B2 · Sphingosine kinase type 1 inhibitors and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,945,971 B2 - Document ID: US10945971B2 - Status: Granted - Kind: B2 - Application number: 16/813,961 - Filed: 2020-03-10 - Published: 2020-06-25 - Granted: 2021-03-16 - Earliest claimed: 2008-04-29 - Assignees: Enzo Therapeutics, Inc.; Virginia Commonwealth University - Applicants: Enzo Therapeutics, Inc.; Virginia Commonwealth University - Inventors: Sarah Spiegel; Robert Elliot Zipkin; Jeffrey Kroll Adams - Web page: https://patentgrep.com/patent/US10945971B2 ## CPC - A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} - A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil - A61P 11/06: Antiasthmatics - A61P 25/04: Centrally acting analgesics, e.g. opioids - C07C 215/28: and containing six-membered aromatic rings - C07C 217/64: with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms - C07C 233/18: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton - C07C 323/32: having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton - C07D 263/06: with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms - C07D 295/092: with aromatic radicals attached to the chain - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) ## Abstract Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke. ## Claims ### Claim 1 A method for treating myocardial infarction in a patient, comprising: administering to a patient in need of treatment for myocardial infarction a compound having the formula ### Claim 2 (depends on 1) The method of claim 1, wherein the administering step comprises administering to the patient. ### Claim 3 (depends on 2) The method of claim 2, wherein administering to the patient comprises administering to the patient. ### Claim 4 A method for treating myocardial infarction in a patient, comprising: administering to a patient in need of treatment for myocardial infarction a compound having the formula wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. ### Claim 5 (depends on 4) The method of claim 4, wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. ### Claim 6 (depends on 5) The method of claim 5, wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring. ### Claim 7 (depends on 6) The method of claim 6, wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms. ### Claim 8 (depends on 7) The method of claim 7, wherein R is a straight carbon chain or a branched carbon chain. ### Claim 9 (depends on 8) The method of claim 8, wherein R is a straight carbon chain. ### Claim 10 A method for treating myocardial infarction in a patient, consisting essentially of: administering to the patient. ### Claim 11 A method for treating stroke in a patient, comprising: administering to a patient in need of treatment for stroke a compound having the formula ### Claim 12 (depends on 11) The method of claim 11, wherein the administering step comprises administering to the patient. ### Claim 13 (depends on 12) The method of claim 12, wherein administering to the patient comprises administering to the patient. ### Claim 14 A method for treating stroke in a patient, comprising: administering to a patient in need of treatment for stroke a compound having the formula wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. ### Claim 15 (depends on 14) The method of claim 14, wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. ### Claim 16 (depends on 15) The method of claim 15, wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring. ### Claim 17 (depends on 16) The method of claim 16, wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms. ### Claim 18 (depends on 17) The method of claim 17, wherein R is a straight carbon chain or a branched carbon chain. ### Claim 19 (depends on 18) The method of claim 18, wherein R is a straight carbon chain. ### Claim 20 A method for treating stroke in a patient, consisting essentially of: administering to the patient.